JSPR Jul 2024 2.500 call
| Previous close | 0.0500 |
| Open | 0.1000 |
| Bid | 2.1000 |
| Ask | 7.0000 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.0500 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireJasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today is presenting preclinical data demonstrating the effect of briquilimab on hematopoietic stem cells (HSCs) at the European Hematolo
Simply Wall St.Here's Why We're Not Too Worried About Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced presentations of data from its preclinical and healthy volunteer studies of briquilimab, as well as trial-in-progress pre
